MedTrace Logo

Effect of Riocigaut on Cerebral Vasodilation and Headache Induction in Healthy Volunteers

NCT05582811 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-01-05

No results posted yet for this study

Summary

This double-blind, randomized, placebo-controlled cross-over clinical trial aims to investigate the effects of riocigaut on cerebral arteries and headache inducing properties in healthy volunteers.

Conditions

Interventions

DRUG

Dose Riociguat 2,5 or 5mg

A selective stimulator of soluble guanylate cyclase (sGC)

DRUG

Riociguat

A selective stimulator of soluble guanylate cyclase (sGC)

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Danish Headache Center

    lead OTHER

Principal Investigators

  • Messoud Ashina, MD · Danish Headache Center

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-26
Primary Completion
2023-06-01
Completion
2023-06-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05582811 on ClinicalTrials.gov